Compare BioNano Genomics Inc (BNGO) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Diamondback Energy Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Diamondback Energy Inc trades at $189.33 (market cap $53.64B). The key difference: Diamondback Energy Inc is far larger — about 4063.6× BioNano Genomics Inc's market cap, and Diamondback Energy Inc pays a 2.31% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FANG | |
|---|---|---|
Market Cap | $13.20M | $53.64B |
Sector | Health | Energy |
52-Week High | $4.92 | $213.69 |
52-Week Low | $1.09 | $134.53 |
Enterprise Value | $15.81M | $67.37B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Diamondback Energy (FANG) trades at $191.6, up 4.48% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $14.93B in 2025, though net income margins have compressed. Recent earnings beat expectations in Q1 2026, and the company maintains a solid balance sheet with manageable debt levels. A dividend of $1.10 was recently paid, enhancing shareholder returns.
FANG presents a favorable outlook with a consensus price target of $234.50, implying significant upside. However, risks include volatile oil prices, declining profit margins, and execution challenges in a competitive energy sector. The stock's high P/E ratio of 195.51 warrants caution, but strong cash flow and institutional bullishness support a positive investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
